Optimized	O
Whole	O
-	O
Genome	O
Amplification	O
Strategy	O
for	O
Extremely	O
AT	O
-	O
Biased	O
Template	O

Edited	O
by	O
Dr	O
Yuji	O
Kohara	O

Pathogen	O
genome	O
sequencing	O
directly	O
from	O
clinical	O
samples	O
is	O
quickly	O
gaining	O
importance	O
in	O
genetic	O
and	O
medical	O
research	O
studies	O
.	O

However	O
,	O
low	O
DNA	O
yield	O
from	O
blood	O
-	O
borne	O
pathogens	O
is	O
often	O
a	O
limiting	O
factor	O
.	O

The	O
problem	O
worsens	O
in	O
extremely	O
base	O
-	O
biased	O
genomes	O
such	O
as	O
the	O
AT	O
-	O
rich	O
Plasmodium	B-OG
falciparum	I-OG
.	O

We	O
present	O
a	O
strategy	O
for	O
whole	O
-	O
genome	O
amplification	O
(	O
WGA	O
)	O
of	O
low	O
-	O
yield	O
samples	O
from	O
P	B-OG
.	I-OG
falciparum	I-OG
prior	O
to	O
short	O
-	O
read	O
sequencing	O
.	O

We	O
have	O
developed	O
WGA	O
conditions	O
that	O
incorporate	O
tetramethylammonium	O
chloride	O
for	O
improved	O
amplification	O
and	O
coverage	O
of	O
AT	O
-	O
rich	O
regions	O
of	O
the	O
genome	O
.	O

We	O
show	O
that	O
this	O
method	O
reduces	O
amplification	O
bias	O
and	O
chimera	O
formation	O
.	O

Our	O
data	O
show	O
that	O
this	O
method	O
is	O
suitable	O
for	O
as	O
low	O
as	O
10	O
pg	O
input	O
DNA	O
,	O
and	O
offers	O
the	O
possibility	O
of	O
sequencing	O
the	O
parasite	O
genome	O
from	O
small	O
blood	O
samples	O
.	O

Introduction	O

Timely	O
detection	O
of	O
emerging	O
genetic	O
variants	O
and	O
other	O
evolutionary	O
features	O
associated	O
with	O
important	O
clinical	O
phenotypes	O
such	O
as	O
increased	O
virulence	O
and	O
drug	O
resistance	O
are	O
central	O
to	O
malaria	B-DS
control	O
strategies	O
.	O

Genome	O
sequencing	O
of	O
parasite	O
populations	O
has	O
been	O
identified	O
as	O
an	O
effective	O
tool	O
for	O
detecting	O
genetic	O
changes	O
.	O
1	O
,	O
2	O
Despite	O
the	O
current	O
success	O
in	O
the	O
sequencing	O
technology	O
,	O
there	O
remain	O
significant	O
challenges	O
in	O
achieving	O
global	O
genetic	O
surveillance	O
of	O
parasite	O
populations	O
in	O
the	O
field	O
.	O

Most	O
genome	O
-	O
scale	O
analyses	O
,	O
such	O
as	O
whole	O
-	O
genome	O
sequencing	O
,	O
require	O
large	O
amounts	O
of	O
clean	O
genetic	O
material	O
that	O
is	O
often	O
difficult	O
to	O
obtain	O
,	O
3	O
and	O
therefore	O
a	O
serious	O
impediment	O
to	O
genetic	O
analysis	O
on	O
many	O
clinical	O
samples	O
.	O

A	O
large	O
number	O
of	O
valuable	O
clinical	O
specimens	O
are	O
collected	O
in	O
the	O
form	O
of	O
small	O
samples	O
that	O
yield	O
low	O
quantity	O
and	O
quality	O
of	O
genetic	O
material	O
.	O
4	O
–	O
7	O
A	O
common	O
method	O
for	O
collecting	O
clinical	O
samples	O
in	O
the	O
field	O
is	O
through	O
heel	O
/	O
finger	O
-	O
pricks	O
.	O
5	O
,	O
7	O
–	O
10	O
However	O
,	O
the	O
quantity	O
and	O
quality	O
of	O
parasite	O
genetic	O
material	O
that	O
can	O
be	O
extracted	O
from	O
these	O
small	O
blood	O
samples	O
usually	O
fall	O
below	O
the	O
threshold	O
required	O
by	O
genome	O
sequencing	O
platforms	O
.	O

To	O
alleviate	O
the	O
problem	O
of	O
low	O
DNA	O
quantities	O
,	O
whole	O
-	O
genome	O
amplification	O
(	O
WGA	O
)	O
is	O
now	O
routinely	O
applied	O
in	O
many	O
applications	O
,	O
3	O
,	O
11	O
but	O
has	O
yet	O
to	O
be	O
optimized	O
for	O
use	O
in	O
genomes	O
of	O
extreme	O
base	O
composition	O
such	O
as	O
Plasmodium	B-OG
falciparum	I-OG
.	O

Two	O
major	O
forms	O
of	O
WGA	O
have	O
been	O
described	O
:	O
multiple	O
displacement	O
amplification	O
(	O
MDA	O
)	O
12	O
,	O
13	O
and	O
PCR	O
-	O
based	O
amplification	O
methods	O
.	O
14	O
,	O
15	O
MDA	O
has	O
been	O
the	O
method	O
of	O
choice	O
for	O
a	O
wider	O
range	O
of	O
genome	O
amplification	O
studies	O
,	O
because	O
it	O
produces	O
longer	O
DNA	O
products	O
with	O
extensive	O
genome	O
coverage	O
.	O
16	O

MDA	O
is	O
based	O
on	O
φ29	O
polymerase	B-GP
,	O
which	O
,	O
in	O
the	O
presence	O
of	O
random	O
hexamers	O
annealed	O
to	O
denatured	O
DNA	O
,	O
uses	O
an	O
MDA	O
mechanism	O
to	O
synthesize	O
high	O
-	O
molecular	O
-	O
weight	O
DNA	O
from	O
very	O
minute	O
amounts	O
of	O
input	O
material	O
under	O
isothermal	O
conditions	O
.	O
17	O
,	O
18	O
The	O
best	O
results	O
,	O
however	O
,	O
have	O
been	O
obtained	O
from	O
genomes	O
with	O
relatively	O
balanced	O
base	O
composition	O
.	O
11	O
,	O
19	O
,	O
20	O
Amplification	O
of	O
genomes	O
with	O
imbalanced	O
base	O
composition	O
,	O
such	O
as	O
the	O
AT	O
-	O
rich	O
P	B-OG
.	I-OG
falciparum	I-OG
,	O
has	O
remained	O
a	O
challenge	O
.	O
21	O
,	O
22	O

In	O
this	O
study	O
,	O
we	O
sought	O
to	O
identify	O
and	O
optimize	O
a	O
WGA	O
system	O
suitable	O
for	O
an	O
AT	O
-	O
base	O
-	O
biased	O
genome	O
of	O
P	B-OG
.	I-OG
falciparum	I-OG
.	O

Using	O
standard	O
conditions	O
as	O
outlined	O
for	O
each	O
system	O
,	O
we	O
tested	O
the	O
efficiency	O
of	O
non	O
-	O
MDA	O
-	O
and	O
MDA	O
-	O
based	O
methods	O
.	O

Initial	O
findings	O
showed	O
that	O
MDA	O
-	O
based	O
systems	O
produced	O
a	O
more	O
uniform	O
genome	O
coverage	O
than	O
non	O
-	O
MDA	O
methods	O
(	O
data	O
not	O
shown	O
).	O

We	O
have	O
optimized	O
an	O
identified	O
MDA	O
system	O
to	O
produce	O
an	O
improved	O
genome	O
coverage	O
and	O
a	O
reduced	O
base	O
-	O
bias	O
with	O
more	O
accurate	O
genome	O
representation	O
.	O

We	O
show	O
that	O
our	O
optimized	O
WGA	O
conditions	O
are	O
suitable	O
for	O
as	O
low	O
as	O
10	O
picograms	O
(	O
pg	O
)	O
P	B-OG
.	I-OG
falciparum	I-OG
input	O
DNA	O
,	O
producing	O
high	O
-	O
sequence	O
concordance	O
with	O
unamplified	O
genomic	O
DNA	O
.	O

This	O
development	O
promises	O
a	O
significant	O
tool	O
to	O
aid	O
implementation	O
of	O
the	O
global	O
genetic	O
surveillance	O
of	O
parasite	O
populations	O
through	O
small	O
blood	O
sample	O
sequencing	O
.	O

Materials	O
and	O
methods	O

DNA	O
samples	O

Plasmodium	B-OG
falciparum	I-OG
3D7	I-OG
genomic	O
DNA	O
was	O
a	O
gift	O
from	O
Prof	O
.	O

Chris	O
Newbold	O
(	O
University	O
of	O
Oxford	O
).	O

The	O
clinical	O
isolates	O
were	O
obtained	O
from	O
the	O
Malaria	B-DS
Genetics	O
Group	O
'	O
s	O
Sequencing	O
Sample	O
Repository	O
at	O
the	O
Wellcome	O
Trust	O
Sanger	O
Institute	O
.	O

Other	O
genomic	O
DNA	O
was	O
extracted	O
from	O
17	O
progeny	O
clones	O
of	O
P	B-OG
.	I-OG
falciparum	I-OG
strains	O
derived	O
from	O
genetic	O
cross	O
between	O
7G8xGB423	O
and	O
a	O
3D7	O
strain	O
(	O
3D7_glasgow	O
).	O

Whole	O
-	O
genome	O
amplification	O

All	O
non	O
-	O
MDA	O
WGA	O
were	O
performed	O
following	O
individual	O
kit	O
manufacturer	O
'	O
s	O
instructions	O
.	O

MDA	O
-	O
based	O
WGA	O
was	O
performed	O
using	O
either	O
REPLI	O
-	O
g	O
Mini	O
kit	O
(	O
Qiagen	O
)	O
or	O
Genomiphi	O
kit	O
(	O
GE	O
Healthcare	O
).	O

For	O
Genomiphi	O
,	O
the	O
kit	O
manufacturer	O
'	O
s	O
instructions	O
were	O
followed	O
without	O
modification	O
.	O

For	O
the	O
REPLI	O
-	O
g	O
Mini	O
kit	O
,	O
manufacturer	O
'	O
s	O
instructions	O
were	O
followed	O
during	O
preliminary	O
tests	O
.	O

The	O
following	O
modifications	O
were	O
performed	O
in	O
developing	O
optimized	O
conditions	O
for	O
the	O
REPLI	O
-	O
g	O
Mini	O
kit	O
:	O
nuclease	B-GP
-	O
free	O
water	O
and	O
all	O
tubes	O
were	O
UV	O
-	O
treated	O
before	O
use	O
.	O

WGA	O
reactions	O
were	O
performed	O
in	O
0	O
.	O
2	O
ml	O
PCR	O
tubes	O
.	O

Buffer	O
D1	O
stock	O
solution	O
(	O
Qiagen	O
)	O
was	O
reconstituted	O
by	O
adding	O
500	O
µl	O
of	O
nuclease	B-GP
-	O
free	O
water	O
,	O
and	O
a	O
working	O
solution	O
was	O
prepared	O
by	O
mixing	O
the	O
stock	O
solution	O
and	O
nuclease	B-GP
-	O
free	O
water	O
in	O
the	O
ratio	O
of	O
1	O
:	O
3	O
.	O
5	O
,	O
respectively	O
.	O

Unmodified	O
Buffer	O
N1	O
was	O
reconstituted	O
by	O
mixing	O
Stop	O
solution	O
(	O
Qiagen	O
)	O
and	O
nuclease	B-GP
-	O
free	O
water	O
in	O
the	O
ratio	O
of	O
1	O
:	O
5	O
.	O
7	O
.	O

Modified	O
buffer	O
N1	O
was	O
prepared	O
by	O
including	O
tetramethylammonium	O
chloride	O
(	O
TMAC	O
)	O
at	O
a	O
concentration	O
of	O
300	O
mM	O
.	O

To	O
denature	O
DNA	O
templates	O
,	O
5	O
µl	O
of	O
the	O
DNA	O
solution	O
was	O
mixed	O
with	O
5	O
µl	O
of	O
buffer	O
D1	O
(	O
working	O
solution	O
prepared	O
as	O
described	O
above	O
).	O

The	O
mixture	O
was	O
vortexed	O
and	O
centrifuged	O
briefly	O
before	O
incubating	O
at	O
room	O
temperature	O
for	O
3	O
min	O
.	O

Denatured	O
DNA	O
was	O
neutralized	O
by	O
adding	O
10	O
µl	O
of	O
either	O
unmodified	O
or	O
modified	O
buffer	O
N1	O
.	O

Neutralized	O
DNA	O
was	O
mixed	O
by	O
vortexing	O
and	O
centrifuged	O
briefly	O
.	O

To	O
amplify	O
the	O
DNA	O
template	O
,	O
denatured	O
and	O
neutralized	O
sample	O
was	O
mixed	O
with	O
29	O
µl	O
of	O
REPLI	O
-	O
g	O
Mini	O
Reaction	O
Buffer	O
and	O
1	O
µl	O
of	O
REPLI	O
-	O
g	O
Mini	O
DNA	B-GP
polymerase	I-GP
to	O
obtain	O
a	O
final	O
reaction	O
volume	O
of	O
50	O
µl	O
.	O

The	O
reaction	O
mixture	O
was	O
incubated	O
at	O
30	O
°	O
C	O
for	O
16	O
h	O
using	O
an	O
MJ	O
Research	O
PTC	O
-	O
225	O
thermal	O
cycling	O
system	O
(	O
GMI	O
,	O
Inc	O
.,	O
USA	O
)	O
with	O
the	O
heating	O
lid	O
set	O
to	O
track	O
at	O
+	O
5	O
°	O
C	O
.	O

Amplified	O
DNA	O
was	O
cleaned	O
using	O
Agencourt	O
Ampure	O
XP	O
beads	O
(	O
Beckman	O
Coulter	O
)	O
using	O
sample	O
to	O
beads	O
ratio	O
of	O
1	O
:	O
1	O
and	O
eluted	O
with	O
50	O
µl	O
of	O
EB	O
(	O
Qiagen	O
).	O

Illumina	O
library	O
preparation	O
and	O
sequencing	O

All	O
sequencing	O
libraries	O
were	O
prepared	O
as	O
PCR	O
-	O
free	O
.	O

Whole	O
-	O
genome	O
amplified	O
or	O
unamplified	O
genomic	O
DNA	O
(	O
1	O
.	O
5	O
μg	O
in	O
75	O
µl	O
of	O
TE	O
buffer	O
)	O
was	O
sheared	O
using	O
a	O
Covaris	O
S2	O
(	O
Covaris	O
,	O
Inc	O
.,	O
Woburn	O
,	O
MA	O
,	O
USA	O
)	O
to	O
obtain	O
a	O
fragment	O
-	O
size	O
distribution	O
of	O
∼	O
300	O
to	O
∼	O
600	O
bp	O
.	O

The	O
sheared	O
DNA	O
fragments	O
were	O
end	O
-	O
repaired	O
and	O
A	O
-	O
tailed	O
using	O
the	O
NEBNext	O
DNA	O
sample	O
preparation	O
kit	O
(	O
NEB	O
),	O
following	O
an	O
Illumina	O
sample	O
preparation	O
protocol	O
.	O

Pre	O
-	O
annealed	O
paired	O
-	O
end	O
Illumina	O
PCR	O
-	O
free	O
adapters	O
were	O
ligated	O
to	O
the	O
A	O
-	O
tailed	O
fragments	O
in	O
a	O
50	O
-	O
µl	O
reaction	O
containing	O
10	O
µl	O
of	O
DNA	O
sample	O
,	O
1	O
×	O
Quick	O
T4	B-OG
DNA	B-GP
ligase	I-GP
buffer	O
,	O
10	O
µl	O
of	O
PCR	O
-	O
free	O
PE	O
-	O
adapter	O
mixture	O
,	O
5	O
µl	O
of	O
Quick	O
T4	B-OG
DNA	B-GP
ligase	I-GP
(	O
NEB	O
)	O
and	O
incubated	O
at	O
20	O
°	O
C	O
for	O
30	O
min	O
.	O

The	O
ligation	O
reaction	O
was	O
cleaned	O
twice	O
using	O
Agencourt	O
Ampure	O
XP	O
beads	O
(	O
Beckman	O
Coulter	O
).	O

Cleaned	O
DNA	O
was	O
eluted	O
with	O
20	O
µl	O
of	O
buffer	O
EB	O
.	O

Aliquots	O
were	O
analysed	O
using	O
an	O
Agilent	O
2100	O
Bioanalyzer	O
(	O
Agilent	O
Technologies	O
)	O
to	O
determine	O
the	O
size	O
distribution	O
and	O
to	O
check	O
for	O
adapter	O
contamination	O
.	O

Samples	O
were	O
sequenced	O
using	O
either	O
Illumina	O
Hiseq	O
2500	O
or	O
Miseq	O
technologies	O
(	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
with	O
75	O
bp	O
read	O
length	O
and	O
the	O
paired	O
-	O
end	O
read	O
options	O
.	O

Corresponding	O
WGA	O
and	O
non	O
-	O
WGA	O
samples	O
were	O
run	O
in	O
the	O
same	O
lanes	O
,	O
using	O
different	O
multiplex	O
tags	O
.	O

This	O
strategy	O
reduces	O
potential	O
confounding	O
artefacts	O
relating	O
to	O
sequencing	O
chemistry	O
.	O

Read	O
mapping	O
and	O
genotype	O
concordance	O
analysis	O

Reads	O
were	O
mapped	O
against	O
the	O
P	B-OG
.	I-OG
falciparum	I-OG
reference	O
sequence	O
(	O
http	O
://	O
plasmodb	O
.	O
org	O
/	O
common	O
/	O
downloads	O
/	O
release	O
-	O
10	O
.	O
0	O
/	O
Pfalciparum3D7	O
/	O
fasta	O
/	O
data	O
/),	O
using	O
BWA	O
(	O
V0	O
.	O
6	O
.	O
2	O
).	O

We	O
analysed	O
the	O
genotype	O
calls	O
from	O
17	O
samples	O
derived	O
from	O
the	O
progeny	O
clones	O
of	O
genetic	O
crosses	O
of	O
7G8xGB4	O
laboratory	O
strains	O
,	O
23	O
including	O
one	O
parent	O
reference	O
strain	O
3D7	O
as	O
a	O
control	O
.	O

For	O
genotype	O
concordance	O
analysis	O
,	O
we	O
generated	O
de	O
novo	O
variation	O
calls	O
using	O
samtools	O
(	O
V0	O
.	O
1	O
.	O
1	O
.	O
19	O
)	O
mpileup	O
and	O
bfctools	O
(	O
V0	O
.	O
1	O
.	O
17	O
),	O
calling	O
on	O
both	O
WGA	O
and	O
non	O
-	O
WGA	O
samples	O
.	O

For	O
in	O
silico	O
genotyping	O
,	O
we	O
used	O
a	O
list	O
of	O
20	O
737	O
high	O
-	O
quality	O
single	O
-	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
positions	O
and	O
alleles	O
generated	O
from	O
the	O
sequence	O
of	O
genetic	O
crosses	O
(	O
unpublished	O
data	O
).	O

We	O
performed	O
in	O
silico	O
genotyping	O
of	O
both	O
the	O
WGA	O
and	O
non	O
-	O
WGA	O
samples	O
using	O
samtools	O
mpileup	O
and	O
counting	O
alleles	O
present	O
in	O
at	O
least	O
five	O
reads	O
.	O

Results	O

WGA	O
using	O
standard	O
methods	O

We	O
performed	O
tests	O
on	O
various	O
WGA	O
systems	O
to	O
identify	O
those	O
suitable	O
for	O
AT	O
-	O
rich	O
P	B-OG
.	I-OG
falciparum	I-OG
genome	O
.	O

We	O
compared	O
non	O
-	O
MDA	O
—	O
Endcore	O
-	O
Rapid	O
(	O
NuGen	O
),	O
MALBAC	O
(	O
Yikon	O
Genomics	O
),	O
Rapisome	O
(	O
Biohelix	O
)	O
and	O
MDA	O
—	O
Repli_g	O
(	O
Qiagen	O
)	O
and	O
Genomiphi	O
(	O
GE	O
Healthcare	O
)	O
systems	O
.	O

Our	O
preliminary	O
data	O
(	O
not	O
shown	O
)	O
indicated	O
that	O
non	O
-	O
MDA	O
methods	O
were	O
less	O
tolerant	O
to	O
the	O
AT	O
-	O
biased	O
genome	O
compared	O
with	O
their	O
MDA	O
counterparts	O
.	O

With	O
non	O
-	O
MDA	O
amplification	O
,	O
we	O
observed	O
excess	O
bias	O
towards	O
regions	O
with	O
high	O
GC	O
content	O
and	O
poor	O
coverage	O
of	O
high	O
AT	O
regions	O
of	O
the	O
genome	O
resulting	O
into	O
high	O
levels	O
of	O
allele	O
dropout	O
.	O

Further	O
optimization	O
focused	O
on	O
the	O
MDA	O
systems	O
.	O

Repli_g	O
and	O
Genomiphi	O
are	O
the	O
most	O
commonly	O
used	O
methods	O
for	O
MDA	O
.	O

Although	O
both	O
kits	O
have	O
shown	O
similar	O
results	O
in	O
many	O
systems	O
,	O
24	O
,	O
25	O
the	O
majority	O
of	O
studies	O
have	O
been	O
with	O
genomes	O
of	O
relatively	O
balanced	O
base	O
composition	O
.	O

Here	O
,	O
we	O
have	O
assessed	O
the	O
performance	O
of	O
Repli_g	O
and	O
Genomiphi	O
by	O
amplifying	O
an	O
AT	O
-	O
rich	O
P	B-OG
.	I-OG
falciparum	I-OG
genome	O
.	O

Amplification	O
of	O
pure	O
P	B-OG
.	I-OG
falciparum	I-OG
3D7	I-OG
genomic	O
DNA	O
by	O
both	O
kits	O
produced	O
very	O
similar	O
results	O
as	O
assessed	O
by	O
genome	O
coverage	O
analysis	O
metrics	O
.	O

However	O
,	O
amplification	O
of	O
host	O
-	O
contaminated	O
clinical	O
samples	O
produced	O
dissimilar	O
results	O
in	O
terms	O
of	O
base	O
composition	O
and	O
overall	O
genome	O
coverage	O
(	O
Fig	O
.	O
1	O
).	O

Whereas	O
amplification	O
products	O
generated	O
by	O
both	O
Repli_g	O
and	O
Genomiphi	O
did	O
not	O
maintain	O
the	O
exact	O
original	O
host	O
/	O
parasite	O
DNA	O
proportions	O
,	O
Genomiphi	O
products	O
were	O
more	O
biased	O
towards	O
the	O
host	O
DNA	O
(	O
Fig	O
.	O
1	O
),	O
an	O
observation	O
suggesting	O
bias	O
towards	O
templates	O
of	O
neutral	O
base	O
composition	O
originating	O
from	O
the	O
host	O
genome	O
.	O

Based	O
on	O
the	O
level	O
of	O
bias	O
,	O
we	O
chose	O
to	O
optimize	O
Repli_g	O
for	O
amplification	O
of	O
the	O
P	B-OG
.	I-OG
falciparum	I-OG
genome	O
.	O
Figure	O
1	O
.	O
Lorenz	O
curves	O
of	O
genome	O
coverage	O
analysis	O
.	O

Cumulative	O
fraction	O
of	O
sequence	O
reads	O
against	O
cumulative	O
fraction	O
of	O
genome	O
covered	O
is	O
shown	O
for	O
each	O
sample	O
.	O

The	O
diagonal	O
line	O
represents	O
an	O
ideal	O
perfect	O
uniform	O
coverage	O
.	O

The	O
further	O
the	O
sample	O
curves	O
deviate	O
from	O
the	O
diagonal	O
line	O
the	O
more	O
bias	O
in	O
genome	O
coverage	O
they	O
are	O
.	O

Repli_g	O
(	O
solid	O
lines	O
)	O
and	O
Genomiphi	O
(	O
dashed	O
lines	O
)	O
sample	O
pairs	O
were	O
normalized	O
to	O
equal	O
number	O
of	O
reads	O
.	O

Repli_g	O
and	O
Genomiphi	O
amplification	O
of	O
P	B-OG
.	I-OG
falciparum	I-OG
3D7	I-OG
genomic	O
DNA	O
(	O
3D7	O
)	O
resulted	O
in	O
identical	O
coverage	O
uniformity	O
as	O
shown	O
in	O
overlapping	O
solid	O
red	O
(	O
Repli_g_3D7	O
)	O
and	O
dashed	O
red	O
(	O
Genomiphi_3D7	O
)	O
curves	O
,	O
respectively	O
.	O

Amplification	O
of	O
clinical	O
samples	O
with	O
varied	O
proportions	O
of	O
human	B-OG
DNA	O
contaminations	O
produced	O
different	O
uniformity	O
of	O
coverage	O
with	O
Genomiphi	O
(	O
dashed	O
lines	O
)	O
showing	O
slightly	O
more	O
bias	O
than	O
their	O
corresponding	O
Repli_g	O
(	O
solid	O
lines	O
)	O
amplified	O
samples	O
.	O

3D7	O
,	O
pure	O
P	B-OG
.	I-OG
falciparum	I-OG
genomic	O
DNA	O
;	O
PK76	O
,	O
clinical	O
sample	O
with	O
53	O
%	O
host	O
DNA	O
contamination	O
amplified	O
with	O
either	O
Genomiphi	O
(	O
Genomiphi_PK76	O
)	O
or	O
Repli_g	O
(	O
Regpli_g_PK76	O
);	O
PD21	O
,	O
a	O
clinical	O
sample	O
with	O
7	O
%	O
host	O
contamination	O
amplified	O
with	O
either	O
Genomiphi	O
(	O
Genomiphi_PD21	O
)	O
or	O
Repli_g	O
(	O
Regpli_g_PD21	O
);	O
PK67	O
,	O
a	O
clinical	O
sample	O
with	O
19	O
%	O
host	O
contamination	O
amplified	O
with	O
either	O
Genomiphi	O
(	O
Genomiphi_PK67	O
)	O
or	O
Repli_g	O
(	O
Regpli_g_PK67	O
).	O

Optimized	O
WGA	O
conditions	O
reduce	O
amplification	O
bias	O
and	O
improve	O
coverage	O
on	O
low	O
complexity	O
regions	O

Non	O
-	O
coding	O
regions	O
of	O
P	B-OG
.	I-OG
falciparum	I-OG
DNA	O
contain	O
∼	O
90	O
%	O
A	O
+	O
T	O
base	O
composition	O
.	O

Amplification	O
of	O
AT	O
-	O
rich	O
genomes	O
is	O
a	O
challenge	O
to	O
almost	O
all	O
commercially	O
available	O
polymerases	B-GP
.	O

We	O
have	O
previously	O
shown	O
that	O
addition	O
of	O
TMAC	O
improves	O
coverage	O
of	O
low	O
GC	O
regions	O
of	O
the	O
genome	O
during	O
PCR	O
,	O
22	O
but	O
the	O
same	O
has	O
not	O
been	O
tested	O
with	O
φ29	O
,	O
the	O
MDA	O
polymerase	B-GP
.	O

To	O
investigate	O
the	O
effect	O
of	O
TMAC	O
on	O
MDA	O
,	O
we	O
amplified	O
P	B-OG
.	I-OG
falciparum	I-OG
3D7	I-OG
genomic	O
DNA	O
of	O
varied	O
input	O
amounts	O
(	O
0	O
.	O
1	O
–	O
2	O
ng	O
)	O
both	O
in	O
the	O
presence	O
and	O
absence	O
of	O
TMAC	O
.	O

We	O
compared	O
the	O
quantity	O
and	O
quality	O
of	O
both	O
products	O
and	O
observed	O
that	O
,	O
like	O
many	O
commercial	O
PCR	O
polymerases	B-GP
,	O
φ29	O
is	O
inhibited	O
by	O
TMAC	O
at	O
certain	O
levels	O
of	O
concentration	O
.	O

We	O
have	O
determined	O
60	O
mM	O
as	O
a	O
concentration	O
that	O
is	O
non	O
-	O
inhibitory	O
to	O
the	O
polymerase	B-GP
and	O
optimal	O
for	O
WGA	O
of	O
an	O
AT	O
-	O
biased	O
genome	O
.	O

Although	O
the	O
quantity	O
of	O
the	O
amplification	O
product	O
was	O
higher	O
in	O
the	O
absence	O
(	O
standard	O
procedure	O
)	O
than	O
in	O
the	O
presence	O
of	O
60	O
mM	O
TMAC	O
(	O
data	O
not	O
shown	O
),	O
the	O
quality	O
of	O
MDA	O
product	O
,	O
in	O
terms	O
of	O
coverage	O
and	O
base	O
composition	O
,	O
was	O
improved	O
in	O
the	O
optimized	O
procedure	O
where	O
TMAC	O
was	O
added	O
(	O
Figs	O
2	O
and	O
3	O
).	O

As	O
shown	O
in	O
Fig	O
.	O
2	O
,	O
amplification	O
using	O
a	O
standard	O
protocol	O
(	O
Std	O
)	O
resulted	O
in	O
excessive	O
bias	O
in	O
regions	O
of	O
low	O
complexity	O
.	O

Inspection	O
of	O
the	O
over	O
-	O
amplified	O
regions	O
reveals	O
sequences	O
of	O
low	O
complexity	O
and	O
numerous	O
repeat	O
patterns	O
.	O

We	O
used	O
a	O
tandem	O
repeat	O
finder	O
programme26	O
and	O
revealed	O
numerous	O
sequences	O
in	O
tandem	O
repeat	O
conformation	O
that	O
may	O
have	O
affected	O
amplification	O
bias	O
.	O

The	O
top	O
three	O
tandem	O
repeats	O
are	O
provided	O
in	O
Supplementary	O
Table	O
S1	O
.	O

Unlike	O
the	O
standard	O
WGA	O
protocol	O
,	O
our	O
optimized	O
amplification	O
procedure	O
abolished	O
excessive	O
amplification	O
bias	O
and	O
produced	O
a	O
more	O
uniform	O
coverage	O
.	O

The	O
mechanism	O
by	O
which	O
this	O
bias	O
is	O
corrected	O
is	O
not	O
clear	O
,	O
but	O
it	O
is	O
conceivable	O
that	O
TMAC	O
stabilizes	O
and	O
stiffens	O
the	O
DNA	O
backbone	O
,	O
thereby	O
minimizing	O
cis	O
-	O
priming	O
by	O
the	O
looping	O
of	O
displaced	O
DNA	O
strands	O
during	O
amplification	O
.	O

We	O
also	O
show	O
that	O
base	O
composition	O
bias	O
increased	O
with	O
a	O
decrease	O
in	O
the	O
amount	O
of	O
input	O
DNA	O
during	O
amplification	O
with	O
standard	O
protocols	O
.	O

This	O
bias	O
was	O
not	O
observed	O
in	O
samples	O
amplified	O
with	O
the	O
optimized	O
(	O
Opt	O
)	O
conditions	O
(	O
Fig	O
.	O
3	O
).	O
Figure	O
2	O
.	O
LookSeq	O
analysis	O
of	O
coverage	O
uniformity	O
.	O
Plasmodium	B-OG
falciparum	I-OG
3D7	I-OG
genomic	O
DNA	O
amplified	O
with	O
Repli_g	O
following	O
standard	O
or	O
optimized	O
procedures	O
.	O

gDNA	O
(	O
top	O
panel	O
)	O
shows	O
bulk	O
genomic	O
DNA	O
sequenced	O
without	O
amplification	O
.	O

All	O
samples	O
amplified	O
using	O
the	O
standard	O
(	O
Std	O
WGA	O
)	O
procedure	O
show	O
regions	O
of	O
amplification	O
bias	O
(	O
marked	O
by	O
*	O
1	O
and	O
*	O
2	O
,	O
see	O
Supplementary	O
Table	O
S1	O
),	O
whereas	O
their	O
corresponding	O
counterparts	O
amplified	O
following	O
the	O
optimized	O
procedure	O
(	O
Optimized	O
WGA	O
)	O
show	O
less	O
bias	O
and	O
relatively	O
uniform	O
coverage	O
.	O

Different	O
amounts	O
of	O
input	O
DNA	O
were	O
used	O
for	O
each	O
sample	O
set	O
(	O
Sample	O
1	O
,	O
0	O
.	O
1	O
ng	O
;	O
Sample	O
2	O
,	O
0	O
.	O
5	O
ng	O
;	O
Sample	O
3	O
,	O
1	O
ng	O
).	O
Figure	O
3	O
.	O
GC	O
content	O
analysis	O
.	O

Different	O
amounts	O
of	O
P	B-OG
.	I-OG
falciparum	I-OG
3D7	I-OG
genomic	O
DNA	O
(	O
ranging	O
from	O
0	O
.	O
1	O
to	O
2	O
ng	O
as	O
shown	O
in	O
sample	O
names	O
)	O
were	O
used	O
as	O
an	O
input	O
template	O
for	O
amplification	O
by	O
Repli_g	O
following	O
the	O
standard	O
or	O
optimized	O
procedure	O
.	O

Amplification	O
products	O
were	O
sequenced	O
as	O
PCR	O
-	O
free	O
and	O
reads	O
obtained	O
were	O
analysed	O
for	O
G	O
+	O
C	O
content	O
profile	O
.	O

A	O
non	O
-	O
WGA	O
sample	O
(	O
gDNA	O
)	O
shows	O
a	O
GC	O
content	O
of	O
∼	O
19	O
.	O
4	O
%,	O
a	O
profile	O
that	O
was	O
closely	O
matched	O
by	O
products	O
amplified	O
using	O
the	O
optimized	O
procedure	O
(	O
Opt	O
).	O

Samples	O
amplified	O
following	O
the	O
standard	O
procedure	O
(	O
Std	O
)	O
showed	O
biased	O
GC	O
content	O
shown	O
as	O
a	O
shift	O
towards	O
the	O
neutral	O
base	O
composition	O
.	O

Optimized	O
conditions	O
reduce	O
chimera	O
formation	O
and	O
maintain	O
template	O
base	O
composition	O
during	O
MDA	O
by	O
φ29	O

Formation	O
of	O
chimeric	O
reads	O
is	O
a	O
major	O
problem	O
with	O
MDA	O
technology	O
.	O
27	O
Chimeras	O
cause	O
serious	O
mapping	O
and	O
assembly	O
problems	O
,	O
and	O
therefore	O
reduce	O
the	O
quality	O
and	O
quantity	O
of	O
the	O
WGA	O
product	O
.	O

We	O
analysed	O
the	O
formation	O
of	O
chimeras	O
by	O
comparing	O
WGA	O
products	O
following	O
standard	O
and	O
optimized	O
procedures	O
.	O

The	O
number	O
of	O
chimeric	O
reads	O
increased	O
as	O
the	O
amount	O
of	O
input	O
DNA	O
was	O
reduced	O
(	O
Fig	O
.	O
4	O
).	O

However	O
,	O
optimizing	O
WGA	O
condition	O
by	O
including	O
TMAC	O
additive	O
decreased	O
the	O
formation	O
of	O
chimeras	O
and	O
improved	O
the	O
quality	O
of	O
reads	O
in	O
P	B-OG
.	I-OG
falciparum	I-OG
WGA	O
.	O
Figure	O
4	O
.	O
Bar	O
graph	O
of	O
chimeric	O
read	O
analysis	O
.	O

Different	O
amounts	O
of	O
P	B-OG
.	I-OG
falciparum	I-OG
3D7	I-OG
genomic	O
DNA	O
(	O
ranging	O
from	O
2	O
ng	O
to	O
100	O
fg	O
as	O
shown	O
in	O
sample	O
labels	O
)	O
were	O
used	O
as	O
an	O
input	O
template	O
for	O
amplification	O
by	O
Repli_g	O
following	O
the	O
standard	O
or	O
optimized	O
procedure	O
.	O

Amplification	O
products	O
were	O
sequenced	O
as	O
PCR	O
-	O
free	O
,	O
and	O
reads	O
obtained	O
were	O
normalized	O
and	O
analysed	O
for	O
the	O
presence	O
of	O
chimeric	O
reads	O
.	O

A	O
non	O
-	O
WGA	O
sample	O
(	O
control	O
)	O
showed	O
the	O
least	O
number	O
of	O
chimers	O
.	O

Using	O
the	O
standard	O
procedure	O
,	O
the	O
number	O
of	O
chimers	O
increased	O
with	O
a	O
decrease	O
in	O
the	O
amount	O
of	O
input	O
DNA	O
.	O

Samples	O
amplified	O
using	O
the	O
optimized	O
procedure	O
showed	O
a	O
decrease	O
in	O
chimer	O
formation	O
that	O
remained	O
low	O
and	O
steady	O
from	O
2	O
ng	O
to	O
100	O
pg	O
of	O
input	O
DNA	O
.	O

WGA	O
from	O
10	O
pg	O
of	O
input	O
P	B-OG
.	I-OG
falciparum	I-OG
genomic	O
DNA	O

Most	O
studies	O
with	O
φ29	O
MDA	O
have	O
used	O
an	O
input	O
DNA	O
of	O
≥	O
10	O
ng	O
for	O
WGA	O
.	O
19	O
,	O
20	O
In	O
many	O
cases	O
,	O
this	O
amount	O
may	O
be	O
difficult	O
to	O
obtain	O
from	O
valuable	O
clinical	O
specimens	O
.	O

We	O
set	O
to	O
find	O
out	O
the	O
minimal	O
amount	O
of	O
parasite	O
DNA	O
that	O
can	O
be	O
successfully	O
amplified	O
by	O
the	O
optimized	O
conditions	O
to	O
obtain	O
uniform	O
genome	O
coverage	O
.	O

We	O
performed	O
WGA	O
on	O
P	B-OG
.	I-OG
falciparum	I-OG
genomic	O
DNA	O
with	O
an	O
input	O
amount	O
ranging	O
from	O
2	O
ng	O
down	O
to	O
100	O
femtograms	O
(	O
fg	O
).	O

WGA	O
products	O
were	O
multiplexed	O
and	O
sequenced	O
using	O
Illumina	O
MiSeq	O
or	O
HiSeq	O
2500	O
machines	O
.	O

Sequence	O
reads	O
generated	O
were	O
analysed	O
to	O
determine	O
the	O
minimum	O
threshold	O
required	O
to	O
produce	O
optimal	O
coverage	O
suitable	O
for	O
various	O
whole	O
-	O
genome	O
studies	O
including	O
genotyping	O
by	O
SNP	O
analysis	O
.	O

To	O
assess	O
the	O
quality	O
of	O
the	O
sequence	O
data	O
generated	O
from	O
each	O
input	O
amount	O
,	O
reads	O
were	O
mapped	O
to	O
the	O
reference	O
genome	O
using	O
BWA	O
.	O

CallableLoci	O
program	O
of	O
the	O
genome	O
analyser	O
tool	O
kit	O
(	O
GATK	O
)	O
28	O
was	O
used	O
to	O
inspect	O
and	O
count	O
the	O
proportion	O
of	O
the	O
genome	O
with	O
high	O
-	O
quality	O
base	O
coverage	O
(	O
callable	O
bases	O
),	O
positions	O
of	O
the	O
genome	O
with	O
zero	O
coverage	O
(	O
uncovered	O
bases	O
)	O
and	O
the	O
size	O
of	O
coverage	O
gaps	O
.	O

Using	O
these	O
metrics	O
,	O
we	O
show	O
that	O
the	O
number	O
of	O
callable	O
loci	O
(	O
high	O
-	O
quality	O
bases	O
)	O
remained	O
relatively	O
high	O
for	O
samples	O
with	O
input	O
DNA	O
ranging	O
from	O
2	O
ng	O
to	O
10	O
pg	O
.	O

However	O
,	O
the	O
quality	O
of	O
sequence	O
data	O
dropped	O
sharply	O
for	O
samples	O
with	O
input	O
DNA	O
<	O
10	O
pg	O
(	O
Fig	O
.	O
5	O
).	O

A	O
similar	O
trend	O
was	O
observed	O
with	O
the	O
proportion	O
of	O
gap	O
sizes	O
(	O
length	O
of	O
uncovered	O
bases	O
,	O
Fig	O
.	O
5	O
bottom	O
panel	O
)	O
and	O
chimeric	O
reads	O
(	O
Fig	O
.	O
4	O
),	O
where	O
a	O
sharp	O
increase	O
in	O
these	O
values	O
was	O
observed	O
for	O
samples	O
with	O
input	O
DNA	O
<	O
10	O
pg	O
.	O

From	O
these	O
observations	O
,	O
we	O
concluded	O
that	O
10	O
pg	O
is	O
the	O
minimal	O
amount	O
of	O
P	B-OG
.	I-OG
falciparum	I-OG
input	O
DNA	O
that	O
produces	O
quality	O
genome	O
coverage	O
under	O
the	O
optimized	O
MDA	O
conditions	O
described	O
.	O

This	O
amount	O
of	O
DNA	O
is	O
equivalent	O
to	O
only	O
∼	O
380	O
parasite	O
genomes	O
.	O
Figure	O
5	O
.	O
Determining	O
the	O
lowest	O
threshold	O
of	O
input	O
DNA	O
mass	O
for	O
WGA	O
.	O

Different	O
amounts	O
of	O
P	B-OG
.	I-OG
falciparum	I-OG
3D7	I-OG
genomic	O
DNA	O
(	O
ranging	O
from	O
2	O
ng	O
to	O
100	O
fg	O
,	O
as	O
shown	O
in	O
sample	O
names	O
)	O
were	O
used	O
as	O
an	O
input	O
template	O
for	O
amplification	O
by	O
Repli_g	O
following	O
the	O
standard	O
or	O
optimized	O
procedure	O
.	O

Samples	O
were	O
multiplexed	O
and	O
sequenced	O
using	O
a	O
fast	O
turn	O
-	O
around	O
Illumina	O
Miseq	O
machine	O
.	O

Sequence	O
reads	O
mapped	O
to	O
the	O
reference	O
were	O
normalized	O
and	O
analysed	O
for	O
coverage	O
and	O
base	O
quality	O
using	O
the	O
‘	O
CallableLoci	O
’	O
program	O
of	O
GATK	O
.	O

A	O
non	O
-	O
WGA	O
sample	O
was	O
used	O
as	O
an	O
unamplified	O
control	O
.	O

Input	O
quantities	O
ranging	O
from	O
2	O
ng	O
down	O
to	O
10	O
pg	O
produced	O
reads	O
with	O
high	O
-	O
quality	O
‘	O
callable	O
’	O
bases	O
covering	O
over	O
60	O
%	O
of	O
the	O
genome	O
.	O

Input	O
DNA	O
below	O
the10	O
-	O
pg	O
threshold	O
produced	O
poor	O
base	O
quality	O
with	O
only	O
<	O
30	O
%	O
of	O
genome	O
covered	O
with	O
‘	O
callable	O
’	O
bases	O
.	O

Input	O
DNA	O
<	O
10	O
pg	O
showed	O
a	O
sharp	O
increase	O
in	O
positions	O
with	O
zero	O
coverage	O
(	O
bases	O
uncovered	O
)	O
and	O
an	O
increase	O
in	O
gap	O
sizes	O
in	O
genome	O
coverage	O
.	O

Detailed	O
analysis	O
of	O
WGA	O
products	O
from	O
a	O
10	O
-	O
pg	O
input	O
template	O
DNA	O

Standard	O
WGA	O
methods	O
produce	O
products	O
that	O
show	O
sequence	O
representation	O
bias	O
,	O
allelic	O
dropout	O
and	O
amplification	O
artefacts	O
.	O

These	O
problems	O
tend	O
to	O
increase	O
as	O
the	O
amount	O
of	O
input	O
template	O
decreases	O
.	O

To	O
adequately	O
evaluate	O
the	O
quality	O
of	O
the	O
WGA	O
products	O
produced	O
from	O
an	O
input	O
of	O
10	O
pg	O
—	O
1	O
,	O
000	O
-	O
fold	O
smaller	O
than	O
the	O
standard	O
input	O
amounts	O
—	O
we	O
performed	O
analysis	O
on	O
genomic	O
DNA	O
extracted	O
from	O
P	B-OG
.	I-OG
falciparum	I-OG
strains	O
derived	O
from	O
the	O
progeny	O
clones	O
of	O
genetic	O
cross	O
between	O
7G8xGB4	O
laboratory	O
strains	O
,	O
as	O
well	O
as	O
the	O
3D7	O
Strain	O
.	O

Genomic	O
DNA	O
extracted	O
from	O
17	O
progeny	O
clones	O
was	O
sequenced	O
both	O
as	O
WGA	O
and	O
as	O
bulk	O
genomic	O
DNA	O
(	O
non	O
-	O
WGA	O
).	O

We	O
performed	O
detailed	O
analysis	O
by	O
comparing	O
sequence	O
data	O
generated	O
from	O
WGA	O
and	O
their	O
matching	O
unamplified	O
genomic	O
DNA	O
(	O
non	O
-	O
WGA	O
).	O

WGA	O
and	O
non	O
-	O
WGA	O
samples	O
yielded	O
a	O
median	O
of	O
3	O
.	O
5	O
and	O
3	O
.	O
4	O
billion	O
base	O
sequences	O
,	O
respectively	O
,	O
with	O
94	O
.	O
8	O
and	O
95	O
.	O
3	O
%	O
of	O
the	O
read	O
mapping	O
to	O
the	O
reference	O
sequence	O
(	O
Table	O
1	O
).	O

WGA	O
samples	O
showed	O
coverage	O
between	O
180	O
×	O
and	O
500	O
×,	O
whereas	O
non	O
-	O
WGA	O
samples	O
showed	O
coverage	O
between	O
90	O
×	O
and	O
250	O
×.	O

A	O
median	O
of	O
1	O
.	O
5	O
and	O
1	O
.	O
2	O
%	O
of	O
genome	O
bases	O
was	O
not	O
covered	O
in	O
WGA	O
and	O
non	O
-	O
WGA	O
samples	O
,	O
respectively	O
(	O
Table	O
1	O
).	O
Table	O
1	O
.	O
Sequence	O
coverage	O
and	O
mapping	O
analysisSampleTotal	O
reads	O
(	O
million	O
)	O
Total	O
base	O
(	O
Gb	O
)	O
Mapped	O
reads	O
(%)	O
Uncovered	O
bases	O
(%)	O
WGANon	O
-	O
WGAWGANon	O
-	O
WGAWGA	O
/	O
non	O
-	O
WGAWGANon	O
-	O
WGAWGANon	O
-	O
WGA3D7_Glasgow30	O
.	O
843	O
.	O
52	O
.	O
33	O
.	O
30	O
.	O
798	O
.	O
898	O
.	O
60	O
.	O
20	O
.	O
0DEV_18_05_1174	O
.	O
550	O
.	O
75	O
.	O
63	O
.	O
81	O
.	O
594	O
.	O
695	O
.	O
01	O
.	O
11	O
.	O
2D2_18_05_1141	O
.	O
741	O
.	O
43	O
.	O
13	O
.	O
11	O
.	O
094	O
.	O
295	O
.	O
21	O
.	O
21	O
.	O
0WE269	O
.	O
735	O
.	O
25	O
.	O
22	O
.	O
62	O
.	O
095	O
.	O
195	O
.	O
11	O
.	O
21	O
.	O
3GB4_NIH45	O
.	O
237	O
.	O
93	O
.	O
42	O
.	O
81	O
.	O
294	O
.	O
294	O
.	O
51	O
.	O
31	O
.	O
1JC345	O
.	O
147	O
.	O
63	O
.	O
43	O
.	O
60	O
.	O
994	O
.	O
395	O
.	O
11	O
.	O
31	O
.	O
1JF649	O
.	O
157	O
.	O
33	O
.	O
74	O
.	O
30	O
.	O
994	O
.	O
395	O
.	O
51	O
.	O
41	O
.	O
1QF546	O
.	O
566	O
.	O
63	O
.	O
55	O
.	O
00	O
.	O
795	O
.	O
295	O
.	O
91	O
.	O
41	O
.	O
2NIC_18_05_1159	O
.	O
136	O
.	O
94	O
.	O
42	O
.	O
81	O
.	O
695	O
.	O
590	O
.	O
61	O
.	O
51	O
.	O
3NF1048	O
.	O
435	O
.	O
03	O
.	O
62	O
.	O
61	O
.	O
495	O
.	O
595	O
.	O
01	O
.	O
51	O
.	O
4XF12_18_05_1139	O
.	O
258	O
.	O
62	O
.	O
94	O
.	O
40	O
.	O
794	O
.	O
795	O
.	O
61	O
.	O
51	O
.	O
2AL2_13_05_1138	O
.	O
340	O
.	O
12	O
.	O
93	O
.	O
01	O
.	O
094	O
.	O
895	O
.	O
41	O
.	O
51	O
.	O
3XD846	O
.	O
945	O
.	O
03	O
.	O
53	O
.	O
41	O
.	O
093	O
.	O
695	O
.	O
51	O
.	O
61	O
.	O
27G8_NIH61	O
.	O
140	O
.	O
54	O
.	O
63	O
.	O
01	O
.	O
594	O
.	O
294	O
.	O
91	O
.	O
61	O
.	O
5JON51	O
.	O
371	O
.	O
83	O
.	O
85	O
.	O
40	O
.	O
794	O
.	O
095	O
.	O
41	O
.	O
61	O
.	O
1TF157	O
.	O
765	O
.	O
24	O
.	O
34	O
.	O
90	O
.	O
995	O
.	O
595	O
.	O
71	O
.	O
81	O
.	O
4JC934	O
.	O
061	O
.	O
32	O
.	O
54	O
.	O
60	O
.	O
695	O
.	O
095	O
.	O
62	O
.	O
51	O
.	O
2Median46	O
.	O
945	O
.	O
03	O
.	O
53	O
.	O
41	O
.	O
094	O
.	O
795	O
.	O
41	O
.	O
51	O
.	O
2Mean	O
±	O
SD49	O
.	O
3	O
±	O
1249	O
.	O
1	O
±	O
123	O
.	O
7	O
±	O
0	O
.	O
93	O
.	O
7	O
±	O
0	O
.	O
91	O
.	O
0	O
±	O
0	O
.	O
494	O
.	O
9	O
±	O
1	O
.	O
295	O
.	O
2	O
±	O
1	O
.	O
51	O
.	O
4	O
±	O
0	O
.	O
41	O
.	O
1	O
±	O
0	O
.	O
3Sequence	O
reads	O
obtained	O
from	O
WGA	O
and	O
non	O
-	O
WGA	O
samples	O
were	O
analysed	O
for	O
coverage	O
and	O
mapping	O
statistics	O
.	O

Nearly	O
identical	O
average	O
number	O
of	O
sequence	O
reads	O
,	O
mapping	O
and	O
coverage	O
statistics	O
were	O
obtained	O
for	O
both	O
WGA	O
and	O
non	O
-	O
WGA	O
datasets	O
.	O

However	O
,	O
coverage	O
distribution	O
was	O
less	O
uniform	O
in	O
WGA	O
compared	O
with	O
non	O
-	O
WGA	O
datasets	O
.	O

Genotype	O
concordance	O
analysis	O

To	O
evaluate	O
the	O
fidelity	O
of	O
sequence	O
representation	O
by	O
WGA	O
,	O
we	O
analysed	O
the	O
genotype	O
calls	O
from	O
17	O
cross	O
samples	O
and	O
the	O
parent	O
reference	O
strain	O
.	O

We	O
performed	O
de	O
novo	O
and	O
in	O
silico	O
genotype	O
calls	O
on	O
sequence	O
generated	O
from	O
both	O
the	O
WGA	O
and	O
non	O
-	O
WGA	O
samples	O
.	O

Genotype	O
concordance	O
was	O
determined	O
by	O
comparing	O
SNP	O
and	O
InDel	O
calls	O
from	O
matched	O
pairs	O
of	O
both	O
non	O
-	O
WGA	O
and	O
WGA	O
samples	O
.	O

Concordance	O
of	O
de	O
novo	O
SNPs	O
and	O
InDel	O
calls	O

For	O
each	O
pair	O
of	O
WGA	O
and	O
non	O
-	O
WGA	O
sample	O
,	O
we	O
generated	O
de	O
novo	O
variation	O
calls	O
simultaneously	O
.	O

A	O
median	O
of	O
20	O
,	O
338	O
biallelic	O
de	O
novo	O
SNPs	O
with	O
a	O
quality	O
score	O
of	O
≥	O
250	O
were	O
called	O
for	O
each	O
sample	O
.	O

For	O
the	O
3D7	O
reference	O
strain	O
(	O
3D7_Glasgow	O
),	O
only	O
185	O
de	O
novo	O
SNPs	O
were	O
called	O
(	O
Supplementary	O
Table	O
S2	O
).	O

Both	O
of	O
these	O
numbers	O
are	O
well	O
within	O
the	O
expected	O
range	O
for	O
this	O
method	O
.	O
1	O
As	O
given	O
in	O
Table	O
2	O
,	O
call	O
pairs	O
were	O
grouped	O
into	O
‘	O
Perfect	O
Concordance	O
’,	O
‘	O
WGA	O
New	O
Alleles	O
’	O
and	O
‘	O
Undetermined	O
’.	O

Identical	O
calls	O
in	O
both	O
non	O
-	O
WGA	O
and	O
WGA	O
samples	O
had	O
a	O
median	O
of	O
97	O
.	O
3	O
%	O
and	O
a	O
mean	O
of	O
96	O
.	O
7	O
%	O
±	O
1	O
.	O
2	O
that	O
are	O
in	O
perfect	O
concordance	O
,	O
and	O
new	O
alleles	O
present	O
only	O
in	O
the	O
WGA	O
samples	O
(	O
considered	O
as	O
WGA	O
-	O
introduced	O
alleles	O
)	O
had	O
a	O
median	O
of	O
1	O
.	O
2	O
%	O
and	O
a	O
mean	O
of	O
1	O
.	O
8	O
±	O
1	O
.	O
1	O
%.	O

Most	O
of	O
the	O
WGA	O
-	O
introduced	O
alleles	O
were	O
due	O
to	O
a	O
mixed	O
call	O
in	O
WGA	O
,	O
where	O
the	O
non	O
-	O
WGA	O
counterpart	O
only	O
showed	O
the	O
reference	O
allele	O
.	O

Discordant	O
single	O
-	O
allele	O
calls	O
were	O
extremely	O
rare	O
with	O
a	O
median	O
of	O
zero	O
SNPs	O
and	O
a	O
total	O
of	O
10	O
occurrences	O
across	O
all	O
the	O
samples	O
(	O
Supplementary	O
Table	O
S2a	O
).	O

Additionally	O
,	O
de	O
novo	O
SNP	O
calls	O
in	O
5	O
,	O
075	O
,	O
789	O
well	O
-	O
covered	O
coding	O
positions	O
(	O
Table	O
2	O
)	O
produced	O
perfect	O
concordance	O
with	O
a	O
median	O
of	O
98	O
.	O
5	O
%	O
and	O
a	O
mean	O
of	O
98	O
.	O
0	O
±	O
1	O
.	O
4	O
%,	O
while	O
the	O
occurrence	O
of	O
WGA	O
-	O
introduced	O
alleles	O
dropped	O
to	O
a	O
median	O
of	O
0	O
.	O
7	O
%	O
and	O
a	O
mean	O
of	O
0	O
.	O
8	O
±	O
0	O
.	O
4	O
%.	O

In	O
this	O
subset	O
,	O
no	O
discordant	O
calls	O
(	O
alt	O
/	O
ref	O
or	O
ref	O
/	O
alt	O
)	O
were	O
observed	O
(	O
Supplementary	O
Table	O
S2b	O
).	O

Calls	O
that	O
were	O
grouped	O
as	O
‘	O
Undetermined	O
’	O
represent	O
alleles	O
that	O
were	O
missing	O
or	O
wrong	O
alleles	O
(	O
present	O
in	O
the	O
non	O
-	O
WGA	O
samples	O
but	O
are	O
neither	O
the	O
reference	O
nor	O
the	O
alternative	O
allele	O
).	O
Table	O
2	O
.	O
WGA	O
and	O
non	O
-	O
WGA	O
SNP	O
concordance	O
analysisSampleDe	O
novo	O
SNP	O
calls	O
in	O
all	O
regionsDe	O
novo	O
SNP	O
calls	O
in	O
good	O
quality	O
regionsPerfect	O
concordance	O
(%)	O
WGA	O
new	O
allele	O
(%)	O
Undetermined	O
(%)	O
Perfect	O
concordance	O
(%)	O
WGA	O
new	O
allele	O
(%)	O
Undetermined	O
(%)	O
JON93	O
.	O
84	O
.	O
41	O
.	O
897	O
.	O
21	O
.	O
61	O
.	O
2JF694	O
.	O
44	O
.	O
31	O
.	O
394	O
.	O
25	O
.	O
00	O
.	O
8D2_18_05_1195	O
.	O
02	O
.	O
62	O
.	O
496	O
.	O
92	O
.	O
20	O
.	O
9QF595	O
.	O
72	O
.	O
51	O
.	O
899	O
.	O
00	O
.	O
50	O
.	O
5QF596	O
.	O
32	O
.	O
61	O
.	O
198	O
.	O
50	O
.	O
80	O
.	O
7JC996	O
.	O
51	O
.	O
61	O
.	O
998	O
.	O
21	O
.	O
30	O
.	O
5XF12_18_05_1197	O
.	O
31	O
.	O
41	O
.	O
498	O
.	O
40	O
.	O
31	O
.	O
2NIC_18_05_1197	O
.	O
30	O
.	O
82	O
.	O
095	O
.	O
62	O
.	O
42	O
.	O
0NF1097	O
.	O
31	O
.	O
51	O
.	O
398	O
.	O
70	O
.	O
50	O
.	O
7DEV_18_05_1197	O
.	O
31	O
.	O
11	O
.	O
698	O
.	O
90	O
.	O
50	O
.	O
5JC397	O
.	O
41	O
.	O
11	O
.	O
698	O
.	O
60	O
.	O
60	O
.	O
8GB4_NIH97	O
.	O
41	O
.	O
11	O
.	O
598	O
.	O
50	O
.	O
50	O
.	O
9AL2_13_05_1197	O
.	O
41	O
.	O
21	O
.	O
499	O
.	O
00	O
.	O
60	O
.	O
5WE297	O
.	O
51	O
.	O
01	O
.	O
697	O
.	O
91	O
.	O
60	O
.	O
57G8_NIH97	O
.	O
51	O
.	O
11	O
.	O
497	O
.	O
12	O
.	O
40	O
.	O
5TF197	O
.	O
61	O
.	O
01	O
.	O
398	O
.	O
80	O
.	O
50	O
.	O
73D7_Glasgow97	O
.	O
81	O
.	O
11	O
.	O
1100	O
.	O
00	O
.	O
00	O
.	O
0Median97	O
.	O
31	O
.	O
21	O
.	O
598	O
.	O
50	O
.	O
60	O
.	O
7Mean	O
±	O
SD96	O
.	O
7	O
±	O
1	O
.	O
21	O
.	O
8	O
±	O
1	O
.	O
11	O
.	O
6	O
±	O
0	O
.	O
398	O
.	O
0	O
±	O
1	O
.	O
41	O
.	O
3	O
±	O
1	O
.	O
20	O
.	O
8	O
±	O
0	O
.	O
4WGA	O
and	O
non	O
-	O
WGA	O
data	O
were	O
analysed	O
for	O
de	O
novo	O
SNP	O
calling	O
concordance	O
.	O

Matching	O
sequence	O
data	O
from	O
cross	O
samples	O
were	O
paired	O
and	O
the	O
SNP	O
calling	O
was	O
performed	O
simultaneously	O
.	O

Concordance	O
rates	O
were	O
generated	O
by	O
comparing	O
WGA	O
and	O
related	O
non	O
-	O
WGA	O
calls	O
.	O

Columns	O
on	O
the	O
left	O
show	O
comparison	O
of	O
all	O
calls	O
covering	O
the	O
entire	O
genome	O
,	O
whereas	O
columns	O
on	O
the	O
right	O
show	O
a	O
subset	O
of	O
all	O
calls	O
covering	O
only	O
the	O
high	O
-	O
quality	O
coding	O
regions	O
of	O
the	O
genome	O
.	O

Values	O
in	O
the	O
perfect	O
concordance	O
columns	O
represent	O
the	O
proportion	O
of	O
calls	O
that	O
were	O
identical	O
in	O
both	O
WGA	O
and	O
non	O
-	O
WGA	O
samples	O
.	O

WGA	O
new	O
allele	O
columns	O
show	O
the	O
proportion	O
of	O
SNPs	O
that	O
were	O
present	O
only	O
in	O
the	O
WGA	O
and	O
not	O
in	O
their	O
matching	O
non	O
-	O
WGA	O
alleles	O
.	O

Undetermined	O
column	O
shows	O
the	O
proportion	O
of	O
SNPs	O
that	O
were	O
called	O
in	O
wrong	O
or	O
missing	O
alleles	O
(	O
Supplementary	O
Table	O
S2	O
).	O

As	O
with	O
SNPs	O
,	O
we	O
also	O
performed	O
biallelic	O
de	O
novo	O
InDel	O
calls	O
with	O
a	O
quality	O
score	O
of	O
≥	O
250	O
for	O
both	O
WGA	O
and	O
non	O
-	O
WGA	O
samples	O
.	O

As	O
given	O
in	O
Table	O
3	O
,	O
InDel	O
calls	O
from	O
the	O
whole	O
genome	O
with	O
perfect	O
concordance	O
between	O
WGA	O
and	O
non	O
-	O
WGA	O
samples	O
had	O
a	O
median	O
of	O
97	O
.	O
6	O
%	O
and	O
a	O
mean	O
of	O
96	O
.	O
8	O
±	O
1	O
.	O
7	O
%,	O
and	O
WGA	O
-	O
introduced	O
InDels	O
had	O
a	O
median	O
of	O
1	O
.	O
5	O
%	O
and	O
a	O
mean	O
of	O
2	O
.	O
4	O
±	O
1	O
.	O
8	O
%.	O

Similarly	O
,	O
de	O
novo	O
InDel	O
calls	O
in	O
the	O
coding	O
regions	O
only	O
produced	O
near	O
-	O
perfect	O
concordance	O
with	O
a	O
median	O
of	O
98	O
.	O
7	O
%	O
and	O
a	O
mean	O
of	O
98	O
.	O
2	O
±	O
1	O
.	O
4	O
%.	O

WGA	O
-	O
introduced	O
InDels	O
in	O
these	O
regions	O
dropped	O
to	O
a	O
median	O
of	O
0	O
.	O
4	O
%	O
and	O
a	O
mean	O
of	O
1	O
.	O
4	O
±	O
1	O
.	O
3	O
%.	O
Table	O
3	O
.	O
WGA	O
and	O
non	O
-	O
WGA	O
InDel	O
concordance	O
analysisSampleDe	O
novo	O
InDel	O
calls	O
in	O
whole	O
genomeDe	O
novo	O
InDel	O
calls	O
in	O
good	O
quality	O
regionsPerfect	O
concordance	O
(%)	O
WGA	O
New	O
InDels	O
(%)	O
UndeterminedPerfect	O
concordance	O
(%)	O
WGA	O
New	O
InDels	O
(%)	O
Undetermined	O
(%)	O
3D7_Glasgow95	O
.	O
24	O
.	O
80	O
.	O
0100	O
.	O
00	O
.	O
00	O
.	O
0JC397	O
.	O
61	O
.	O
50	O
.	O
998	O
.	O
80	O
.	O
80	O
.	O
4QF597	O
.	O
22	O
.	O
10	O
.	O
696	O
.	O
13	O
.	O
60	O
.	O
3JF691	O
.	O
57	O
.	O
80	O
.	O
796	O
.	O
53	O
.	O
40	O
.	O
2TF198	O
.	O
21	O
.	O
20	O
.	O
599	O
.	O
40	O
.	O
50	O
.	O
1DEV_18_05_1198	O
.	O
11	O
.	O
00	O
.	O
899	O
.	O
20	O
.	O
30	O
.	O
57G8_NIH97	O
.	O
91	O
.	O
20	O
.	O
898	O
.	O
70	O
.	O
60	O
.	O
8GB4_NIH97	O
.	O
91	O
.	O
20	O
.	O
998	O
.	O
60	O
.	O
70	O
.	O
7WE298	O
.	O
01	O
.	O
10	O
.	O
999	O
.	O
00	O
.	O
70	O
.	O
3D2_18_05_1195	O
.	O
82	O
.	O
51	O
.	O
797	O
.	O
11	O
.	O
61	O
.	O
3NIC_18_05_1197	O
.	O
81	O
.	O
01	O
.	O
299	O
.	O
10	O
.	O
30	O
.	O
6NF1097	O
.	O
41	O
.	O
80	O
.	O
898	O
.	O
31	O
.	O
10	O
.	O
6XF12_18_05_1198	O
.	O
01	O
.	O
40	O
.	O
699	O
.	O
00	O
.	O
60	O
.	O
4AL2_13_05_1197	O
.	O
71	O
.	O
50	O
.	O
899	O
.	O
30	O
.	O
30	O
.	O
3XD895	O
.	O
53	O
.	O
90	O
.	O
795	O
.	O
73	O
.	O
60	O
.	O
7JON95	O
.	O
24	O
.	O
20	O
.	O
696	O
.	O
13	O
.	O
70	O
.	O
3JC996	O
.	O
42	O
.	O
90	O
.	O
798	O
.	O
41	O
.	O
50	O
.	O
1Median97	O
.	O
61	O
.	O
50	O
.	O
898	O
.	O
70	O
.	O
70	O
.	O
4Mean	O
±	O
SD96	O
.	O
8	O
±	O
1	O
.	O
72	O
.	O
4	O
±	O
1	O
.	O
80	O
.	O
8	O
±	O
0	O
.	O
398	O
.	O
2	O
±	O
1	O
.	O
41	O
.	O
4	O
±	O
1	O
.	O
30	O
.	O
4	O
±	O
0	O
.	O
3WGA	O
and	O
non	O
-	O
WGA	O
data	O
were	O
analysed	O
for	O
de	O
novo	O
InDel	O
calling	O
concordance	O
.	O

Calls	O
were	O
performed	O
simultaneously	O
on	O
both	O
WGA	O
and	O
related	O
non	O
-	O
WGA	O
.	O

Columns	O
on	O
the	O
left	O
show	O
comparison	O
of	O
all	O
calls	O
covering	O
the	O
entire	O
genome	O
,	O
whereas	O
columns	O
on	O
the	O
right	O
show	O
a	O
subset	O
of	O
all	O
calls	O
covering	O
only	O
the	O
high	O
-	O
quality	O
coding	O
regions	O
of	O
the	O
genome	O
.	O

Values	O
in	O
the	O
perfect	O
concordance	O
columns	O
represent	O
the	O
proportion	O
of	O
calls	O
that	O
were	O
identical	O
in	O
both	O
WGA	O
and	O
non	O
-	O
WGA	O
samples	O
.	O

WGA	O
new	O
allele	O
columns	O
show	O
the	O
proportion	O
of	O
InDels	O
that	O
were	O
present	O
only	O
in	O
the	O
WGA	O
and	O
not	O
in	O
their	O
matching	O
non	O
-	O
WGA	O
alleles	O
.	O

Undetermined	O
column	O
shows	O
the	O
proportion	O
of	O
InDels	O
that	O
were	O
called	O
in	O
wrong	O
or	O
missing	O
alleles	O
(	O
Supplementary	O
Table	O
S3	O
).	O

Concordance	O
of	O
in	O
silico	O
genotyping	O

Using	O
a	O
list	O
of	O
high	O
-	O
quality	O
SNP	O
positions	O
and	O
alleles	O
from	O
the	O
genetic	O
crosses	O
,	O
we	O
performed	O
in	O
silico	O
genotyping	O
of	O
both	O
the	O
WGA	O
and	O
non	O
-	O
WGA	O
samples	O
on	O
20	O
,	O
737	O
positions	O
,	O
counting	O
alleles	O
present	O
in	O
at	O
least	O
five	O
reads	O
.	O

Call	O
comparisons	O
between	O
the	O
WGA	O
and	O
non	O
-	O
WGA	O
from	O
same	O
samples	O
were	O
grouped	O
into	O
‘	O
Perfect	O
Concordance	O
(	O
identical	O
)’,	O
‘	O
WGA	O
Missing	O
Alleles	O
’,	O
‘	O
WGA	O
New	O
Alleles	O
’	O
and	O
‘	O
Undetermined	O
’	O
(	O
missing	O
allele	O
).	O

Identical	O
alleles	O
with	O
perfect	O
concordance	O
between	O
WGA	O
and	O
non	O
-	O
WGA	O
samples	O
had	O
a	O
median	O
of	O
97	O
.	O
95	O
%	O
(	O
Fig	O
.	O
6	O
).	O

A	O
median	O
of	O
0	O
.	O
48	O
%	O
calls	O
represent	O
alleles	O
that	O
were	O
called	O
in	O
the	O
WGA	O
,	O
but	O
not	O
in	O
the	O
non	O
-	O
WGA	O
,	O
samples	O
.	O

These	O
reflect	O
cases	O
where	O
the	O
WGA	O
sample	O
had	O
a	O
mixed	O
call	O
and	O
the	O
non	O
-	O
WGA	O
sample	O
had	O
a	O
single	O
-	O
allele	O
call	O
.	O

A	O
median	O
of	O
0	O
.	O
94	O
%	O
represent	O
alleles	O
that	O
were	O
missing	O
in	O
WGA	O
,	O
but	O
were	O
called	O
in	O
non	O
-	O
WGA	O
samples	O
.	O

Discordant	O
single	O
-	O
allele	O
calls	O
were	O
extremely	O
rare	O
,	O
with	O
a	O
median	O
of	O
zero	O
and	O
a	O
mean	O
of	O
2	O
.	O
9	O
SNPs	O
per	O
sample	O
.	O

Four	O
of	O
the	O
17	O
samples	O
showed	O
such	O
discordant	O
calls	O
,	O
and	O
only	O
three	O
samples	O
had	O
more	O
than	O
one	O
such	O
call	O
.	O

The	O
3D7	O
(	O
3D7_Glasgow	O
)	O
reference	O
sample	O
showed	O
99	O
.	O
58	O
%	O
identical	O
calls	O
,	O
and	O
only	O
one	O
new	O
allele	O
in	O
WGA	O
sample	O
was	O
returned	O
as	O
a	O
mixed	O
call	O
(	O
Supplementary	O
Table	O
S4	O
).	O
Figure	O
6	O
.	O
Boxplot	O
of	O
in	O
silico	O
genotyping	O
concordance	O
analysing	O
.	O

A	O
total	O
of	O
20	O
,	O
737	O
high	O
-	O
quality	O
SNP	O
positions	O
were	O
genotyped	O
in	O
both	O
WGA	O
and	O
non	O
-	O
WGA	O
samples	O
.	O

Call	O
comparison	O
was	O
performed	O
between	O
matched	O
pairs	O
of	O
corresponding	O
WGA	O
and	O
non	O
-	O
WGA	O
datasets	O
and	O
results	O
were	O
grouped	O
into	O
‘	O
Perfect	O
Concordance	O
’,	O
‘	O
WGA	O
Missing	O
Alleles	O
’,	O
‘	O
WGA	O
New	O
Alleles	O
’	O
and	O
‘	O
Undetermined	O
’.	O

Perfect_Concordance	O
(	O
identical	O
alleles	O
)	O
had	O
a	O
median	O
of	O
97	O
.	O
95	O
%	O
(	O
range	O
83	O
.	O
11	O
–	O
99	O
.	O
58	O
%;	O
n	O
=	O
17	O
).	O

A	O
median	O
of	O
0	O
.	O
48	O
%	O
calls	O
represent	O
alleles	O
that	O
were	O
called	O
in	O
the	O
WGA	O
samples	O
,	O
but	O
not	O
in	O
the	O
non	O
-	O
WGA	O
samples	O
(	O
WGA_New_Alleles	O
).	O

A	O
median	O
of	O
0	O
.	O
94	O
%	O
calls	O
were	O
present	O
in	O
non	O
-	O
WGA	O
,	O
but	O
absent	O
in	O
WGA	O
,	O
samples	O
(	O
WGA_Missing_Alleles	O
).	O

The	O
proportion	O
of	O
calls	O
that	O
were	O
missing	O
(	O
Undetermined	O
)	O
had	O
a	O
median	O
of	O
0	O
.	O
96	O
%	O
(	O
Supplementary	O
Table	O
S4	O
).	O

Discussion	O

High	O
-	O
throughput	O
DNA	O
sequencing	O
technologies	O
have	O
gained	O
a	O
wide	O
range	O
of	O
applications	O
in	O
infectious	B-DS
disease	I-DS
research	O
,	O
including	O
global	O
surveillance	O
of	O
the	O
emergence	O
and	O
spread	O
of	O
drug	O
resistance	O
,	O
detection	O
of	O
regions	O
of	O
the	O
genome	O
under	O
selection	O
and	O
identification	O
of	O
genetic	O
determinants	O
of	O
clinical	O
phenotypes	O
through	O
genome	O
-	O
wide	O
association	O
studies	O
.	O

The	O
P	B-OG
.	I-OG
falciparum	I-OG
genome	O
presents	O
inherent	O
technical	O
challenges	O
to	O
next	O
-	O
generation	O
DNA	O
sequencing	O
,	O
such	O
as	O
its	O
extreme	O
AT	O
-	O
richness	O
.	O

Whole	O
-	O
genome	O
sequencing	O
of	O
P	B-OG
.	I-OG
falciparum	I-OG
field	O
isolates	O
poses	O
additional	O
difficulties	O
due	O
to	O
the	O
small	O
quantity	O
of	O
DNA	O
often	O
retrieved	O
from	O
patients	O
in	O
the	O
clinical	O
setting	O
and	O
the	O
high	O
degree	O
of	O
host	O
DNA	O
contamination	O
from	O
leucocytes	O
.	O

This	O
study	O
addressed	O
the	O
first	O
of	O
these	O
key	O
problems	O
by	O
developing	O
a	O
method	O
for	O
WGA	O
capable	O
of	O
producing	O
high	O
-	O
quality	O
sequence	O
data	O
from	O
just	O
10	O
pg	O
of	O
input	O
P	B-OG
.	I-OG
falciparum	I-OG
DNA	O
.	O

Although	O
PCR	O
-	O
based	O
WGA	O
techniques	O
,	O
such	O
as	O
primer	O
extension	O
PCR	O
,	O
ligation	O
-	O
mediated	O
PCR	O
and	O
degenerate	O
oligonucleotide	O
-	O
primed	O
PCR	O
,	O
have	O
been	O
successfully	O
used	O
in	O
some	O
studies	O
such	O
as	O
single	O
-	O
cell	O
amplification	O
,	O
29	O
their	O
wider	O
application	O
has	O
been	O
limited	O
.	O

PCR	O
-	O
based	O
WGA	O
methods	O
produce	O
relatively	O
shorter	O
products	O
,	O
non	O
-	O
specific	O
amplification	O
artefacts	O
and	O
incomplete	O
genome	O
coverage	O
.	O
19	O
,	O
20	O
,	O
30	O
MDA	O
has	O
been	O
associated	O
with	O
base	O
-	O
bias	O
and	O
generation	O
of	O
chimeric	O
products	O
.	O
29	O
Nonetheless	O
,	O
MDA	O
has	O
been	O
the	O
method	O
of	O
choice	O
for	O
a	O
wider	O
range	O
of	O
genome	O
amplification	O
studies	O
,	O
because	O
it	O
produces	O
longer	O
DNA	O
products	O
with	O
extensive	O
genome	O
coverage	O
.	O

MDA	O
also	O
produces	O
higher	O
DNA	O
yields	O
with	O
relatively	O
less	O
amplification	O
bias	O
.	O
3	O
,	O
11	O
,	O
19	O

Here	O
,	O
we	O
have	O
assessed	O
MDA	O
on	O
an	O
AT	O
-	O
rich	O
genome	O
using	O
a	O
range	O
of	O
input	O
DNA	O
quantities	O
.	O

We	O
describe	O
an	O
optimized	O
WGA	O
method	O
incorporating	O
TMAC	O
reagent	O
that	O
improves	O
amplification	O
coverage	O
of	O
the	O
difficult	O
AT	O
-	O
rich	O
loci	O
of	O
the	O
genome	O
.	O

We	O
establish	O
10	O
pg	O
of	O
input	O
DNA	O
as	O
the	O
lowest	O
threshold	O
from	O
which	O
our	O
optimized	O
WGA	O
protocol	O
generates	O
an	O
amplification	O
product	O
with	O
optimal	O
P	B-OG
.	I-OG
falciparum	I-OG
genome	O
coverage	O
for	O
most	O
genome	O
sequencing	O
analysis	O
.	O

This	O
amount	O
equates	O
to	O
∼	O
380	O
parasite	O
genomes	O
,	O
equivalent	O
to	O
∼	O
1	O
µl	O
of	O
blood	O
in	O
a	O
patient	O
with	O
0	O
.	O
01	O
%	O
parasitemia	B-DS
.	O

Furthermore	O
,	O
we	O
show	O
that	O
the	O
optimized	O
conditions	O
significantly	O
reduce	O
the	O
formation	O
of	O
chimeric	O
reads	O
,	O
thereby	O
improving	O
the	O
overall	O
quality	O
of	O
the	O
amplified	O
product	O
.	O

Standard	O
WGA	O
from	O
such	O
small	O
quantities	O
of	O
input	O
material	O
is	O
often	O
associated	O
with	O
bias	O
and	O
incomplete	O
genome	O
coverage	O
.	O

A	O
single	O
-	O
cell	O
genomic	O
approach	O
that	O
uses	O
infected	O
red	O
blood	O
cell	O
sorting	O
technology	O
has	O
recently	O
been	O
reported	O
that	O
achieved	O
a	O
genome	O
coverage	O
of	O
∼	O
50	O
%	O
with	O
a	O
standard	O
WGA	O
method	O
.	O
31	O
Although	O
genome	O
coverage	O
in	O
single	O
-	O
cell	O
approach	O
is	O
still	O
low	O
,	O
this	O
technology	O
has	O
opened	O
avenues	O
for	O
single	O
-	O
cell	O
genomics	O
studies	O
in	O
malaria	B-DS
and	O
offers	O
great	O
opportunities	O
for	O
dissecting	O
multiple	O
genotype	O
infection	B-DS
.	O

Our	O
optimized	O
WGA	O
method	O
described	O
here	O
will	O
be	O
useful	O
for	O
optimizing	O
genome	O
coverage	O
in	O
such	O
single	O
-	O
cell	O
genome	O
amplifications	O
,	O
as	O
well	O
as	O
direct	O
field	O
applications	O
for	O
small	O
sample	O
sequencing	O
.	O

For	O
improved	O
malaria	B-DS
clinical	O
sequencing	O
,	O
we	O
routinely	O
employ	O
the	O
combination	O
of	O
host	O
depletion	O
methods32	O
,	O
33	O
and	O
the	O
current	O
optimized	O
WGA	O
procedure	O
to	O
generate	O
high	O
-	O
quality	O
whole	O
genome	O
sequencing	O
data	O
.	O

We	O
have	O
assessed	O
the	O
quality	O
of	O
the	O
amplified	O
products	O
generated	O
from	O
10	O
pg	O
input	O
DNA	O
using	O
high	O
-	O
throughput	O
sequencing	O
of	O
DNA	O
extracted	O
from	O
17	O
progeny	O
clones	O
derived	O
from	O
genetic	O
crosses	O
between	O
two	O
laboratory	O
strains	O
.	O

We	O
performed	O
a	O
comparative	O
analysis	O
between	O
the	O
WGA	O
data	O
and	O
their	O
corresponding	O
non	O
-	O
WGA	O
counterparts	O
.	O

We	O
show	O
that	O
coverage	O
was	O
sufficient	O
for	O
allele	O
calling	O
and	O
other	O
whole	O
-	O
genome	O
analyses	O
.	O

Although	O
the	O
number	O
of	O
uncovered	O
bases	O
was	O
slightly	O
higher	O
in	O
WGA	O
(	O
median	O
,	O
1	O
.	O
5	O
%)	O
than	O
non	O
-	O
WGA	O
(	O
median	O
,	O
1	O
.	O
2	O
%)	O
samples	O
(	O
Table	O
1	O
),	O
the	O
difference	O
was	O
insignificant	O
(	O
t	O
-	O
test	O
,	O
P	O
=	O
0	O
.	O
053	O
,	O
95	O
%	O
CI	O
).	O

The	O
same	O
applies	O
to	O
preference	O
for	O
mitochondria	O
DNA	O
amplification	O
,	O
which	O
showed	O
a	O
median	O
of	O
2	O
.	O
6	O
%	O
in	O
WGA	O
against	O
0	O
.	O
6	O
%	O
in	O
the	O
non	O
-	O
WGA	O
samples	O
.	O

Another	O
key	O
aspect	O
of	O
P	B-OG
.	I-OG
falciparum	I-OG
whole	O
-	O
genome	O
sequencing	O
from	O
clinical	O
specimens	O
is	O
removing	O
host	O
DNA	O
contamination	O
.	O

This	O
can	O
be	O
achieved	O
either	O
at	O
the	O
blood	O
sample	O
processing	O
stage	O
through	O
leucocyte	O
depletion	O
or	O
through	O
selective	O
enrichment	O
of	O
parasite	O
DNA	O
after	O
extraction	O
.	O
32	O
–	O
34	O
The	O
combination	O
of	O
an	O
effective	O
method	O
for	O
removing	O
human	B-OG
DNA	O
that	O
is	O
applicable	O
to	O
the	O
field	O
setting	O
,	O
and	O
the	O
ability	O
to	O
perform	O
whole	O
-	O
genome	O
sequencing	O
from	O
very	O
low	O
quantities	O
of	O
input	O
DNA	O
as	O
described	O
in	O
this	O
study	O
,	O
has	O
the	O
potential	O
to	O
greatly	O
increase	O
the	O
scope	O
and	O
scale	O
of	O
P	B-OG
.	I-OG
falciparum	I-OG
genomic	O
research	O
.	O

This	O
,	O
in	O
turn	O
,	O
would	O
contribute	O
significantly	O
to	O
malaria	B-DS
genetic	O
surveillance	O
and	O
control	O
strategies	O
.	O

Conclusion	O

The	O
optimized	O
amplification	O
conditions	O
described	O
here	O
have	O
generated	O
high	O
-	O
quality	O
whole	O
-	O
genome	O
sequence	O
data	O
(	O
99	O
.	O
8	O
%	O
genome	O
coverage	O
)	O
from	O
a	O
minute	O
amount	O
of	O
input	O
DNA	O
,	O
equivalent	O
to	O
<	O
400	O
P	B-OG
.	I-OG
falciparum	I-OG
genomes	O
.	O

This	O
work	O
shows	O
for	O
the	O
first	O
time	O
that	O
accurate	O
in	O
silico	O
genotyping	O
and	O
de	O
novo	O
calling	O
of	O
genetic	O
variants	O
is	O
achievable	O
on	O
a	O
WGA	O
sample	O
using	O
<	O
1	O
ng	O
of	O
input	O
DNA	O
from	O
an	O
extremely	O
AT	O
-	O
rich	O
genome	O
.	O

We	O
anticipate	O
that	O
sequencing	O
from	O
small	O
quantities	O
of	O
input	O
DNA	O
(<	O
1	O
ng	O
)	O
will	O
become	O
a	O
significant	O
aid	O
to	O
genetic	O
and	O
genomic	O
studies	O
of	O
P	B-OG
.	I-OG
falciparum	I-OG
in	O
the	O
field	O
,	O
particularly	O
when	O
combined	O
with	O
effective	O
methods	O
for	O
removal	O
of	O
host	O
DNA	O
contamination	O
.	O

Supplementary	O
Data	O

Supplementary	O
Data	O
are	O
available	O
at	O
www	O
.	O
dnaresearch	O
.	O
oxfordjournals	O
.	O
org	O
.	O

Supplementary	O
Material	O

Supplementary	O
Data	O

